Cowen started coverage on shares of Rockley Photonics (NYSE:RKLY) in a report published on Thursday morning, The Fly reports. The brokerage issued an outperform rating and a $22.00 price objective on the stock.
RKLY has been the topic of several other research reports. Robert W. Baird initiated coverage on shares of Rockley Photonics in a report on Wednesday, August 25th. They issued an outperform rating and a $18.00 target price on the stock. Needham & Company LLC initiated coverage on shares of Rockley Photonics in a report on Tuesday, September 7th. They issued a buy rating and a $15.00 target price on the stock.
Get Rockley Photonics alerts:
Shares of RKLY opened at $9.80 on Thursday. The stock has a market cap of $1.24 billion, a PE ratio of 245.00 and a beta of -0.02. Rockley Photonics has a 1 year low of $6.81 and a 1 year high of $16.56.
Top 5 Heal Care Stocks To Invest In 2023: OncoMed Pharmaceuticals, Inc.(OMED)
OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, discovers and develops protein therapeutics targeting cancer stem cells (CSCs). Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, as well as impact bulk tumor cells. The companys product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), a humanized monoclonal antibody that is in two Phase II clinical trials and one Phase Ib/II clinical trial for the treatment of patients with non-small-cell lung cancer and pancreatic cancer; Anti-DLL4/Anti-vascular endothelial growth factor (VEGF) Bispecific, which has completed preclinical trial that targets and inhibits DLL4 and vascular endothelial growth factor (VEGF); Tarextumab (Anti-Notch2/3, OMP-59R5), a human monoclonal antibody that targets the Notch2 and Notch3 receptors that is in Phase II clinical trials; Brontictuzumab (Anti-Notch1, OMP-52M51), a human monoclonal antibody, which completed single-agent Phase I trial for the treatment of solid tumor; and Vantictumab ((Anti-Fzd7, OMP-18R5) that completed a Phase I single-agent trial in tumor patients. Its products also include Ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based Frizzled8 receptor or Fzd8, which is in Phase I single agent trial; Wnt biologic #3, an additional bispecific biologic product candidate in preclinical studies; Wnt small molecule inhibitors, which is in preclinical testing; and RSPO-LGR, a CSC pathway that is in preclinical study of antibodies. OncoMed Pharmaceuticals, Inc. has strategic alliances with GlaxoSmithKline LLC to develop anti-CSC antibody therapeutics targeting the Notch signaling pathway; Bayer Pharma AG for anti-CSC biologic and small molecule therapeutics targeting the Wnt signaling pathway; and Celgene Corporation for anti-CSC product candidates. The company was founded in 2004 and is headquartered in Redwood City, California.